ICMR Gets CDSCO Approval For Clinical Trial Of Convalescent Plasma In Covid-19 Patients
ICMR Gets CDSCO Approval For Clinical Trial Of Convalescent Plasma In Covid-19 PatientsICMR Logo

The Central Drugs Standard Control Organisation (CDSCO), India’s apex drug regulator body, has approved the proposal of Indian Council for Medical Research (ICMR) for conducting clinical trial of convalescent plasma in Covid-19 patients, as per the protocol developed by the ICMR, reports Economic Times.

The Drug Controller General of India in a notice issued on Friday (17 April) said that its subject expert committee (SEC) reviewed the ICMR’s proposal and based on its regulation, the CDSCO has conveyed no objection for conduct of clinical trial.

"It is to inform that in light of public interest the proposal of ICMR for conducting the said trial has been reviewed through the Subject Expert Committee in its meeting held on April 13 under accelerated approval process in light of the current prevailing situation of COVID-19 and based on the recommendation of the committee,” the central drug regulator said in the notice.

"The CDSCO has conveyed its no objection for conduct of the clinical trial subject to certain amendments in the protocol and various conditions under the Drugs and Clinical Trial Rules 2019," it added.

In convalescent plasma therapy, the treatment of severely infected patients will be done using antibodies from the blood of patients who have recovered from Covid-19.

Further, the notice said that ICMR has submitted a list of institutes to CDSCO which have shown an interest in the conduct of the trial.

The notice underlined that ICMR has developed a protocol for a controlled clinical trial with convalescent plasma in moderate COVID-19 patients which has been reviewed by the committee and the same may also be considered by the applicants as appropriate.

An Appeal...

Dear Reader,

As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.

Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.

We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.

Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.

Become A Patron
Become A Subscriber